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The Senataxin (SETX) protein exhibits strong sequence conservation with the helicase domain of the yeast protein
Sen1p, and recessive SETX mutations cause a severe ataxia, known as Ataxia with Oculomotor Apraxia type 2,
while dominant SETX mutations cause Amyotrophic Lateral Sclerosis type 4. SETX is a very low abundance
protein, and its expression is tightly regulated, such that large increases in mRNA levels fail to significantly in-
crease protein levels. Despite this, transient transfection in cell culture can boost SETX protein levels on an in-
dividual cell basis. Here we found that over-expression of normal SETX, but not enzymatically-dead SETX, is
associated with S-phase cell-cycle arrest in HEK293A cells. As SETX interacts with the nuclear exosome to ensure
degradation of incomplete RNA transcripts, and SETX localizes to sites of collision between the DNA replication
machinery and the RNAP II complex, altered dosage or aberrant function of SETX may impede this process to
promote S-phase cell-cycle arrest. Because neurons are enriched for long transcripts with additional antisense
regulatory transcription, collisions of RNAP II complexes may occur in such post-mitotic cells, underscoring a role
for SETX in maintaining neuron homeostasis.1. Introduction
The study of SETX is of significant clinical interest, as recessive loss-
of-function mutations cause a severe ataxia, known as Ataxia with Ocu-
lomotor Apraxia type 2 (AOA2; OMIM: 606002). More than 150 different
SETX mutations have been identified to date, Human Gene Mutation
Database (HGMD) [1], and the majority of these are loss-of-function
mutations found in patients with AOA2. Unlike related ataxias, such as
ataxia-telangiectasia (A-T) [2], AOA2 patients do not display an
increased risk of cancer [3], suggesting that SETX is not directly involved
in canonical DNA damage repair pathways. Interestingly though, both
AOA2 and A-T patients show elevated serum levels of alpha-feto-protein
[4], the most abundant fetal plasma protein.
Dominant SETXmutations also cause a juvenile-onset form of familial
Motor Neuron Disease (MND), known as ALS4 [5]. ALS4 is unusual in
that it is non-fatal, shows symmetrical distribution, and has little to nonnett).
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vier Ltd. This is an open access arbulbar involvement [6]. ALS4-linked mutations are rare, with the L389S
substitution located in the ‘protein interaction domain’ reported in at
least three independent pedigrees with similar motor-specific pheno-
types [5, 7, 8]. In one large American pedigree, > 50 affected members
segregate the L389S mutation, confirming its pathogenicity [9].
ALS4-linked mutations likely act through a toxic gain-of-function
mechanism, as AOA2 heterozygous carriers do not develop neurologic
disease and remain symptom-free with age [10].
SETX is a large 2,677 amino acid (aa) protein defined by one highly
conserved helicase domain (residues 1931–2456), with homology to only
two other human proteins, Rent1 and IGHMBP2. Rent1 is an essential
component of the nonsense-mediated RNA decay (NMD) complex [11],
and recessive mutations of the IGHMBP2 gene cause a fatal disorder,
Spinal Muscle Atrophy with Respiratory Distress (SMARD) [12]. Studies
suggest that SETX may aid in the resolution of R-loops that form when
newly transcribed RNA hybridizes back to the coding DNA strand [13,ingdom.
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neurodegenerative disease remains unknown. Setx knock-out mice
exhibit no obvious R-loop resolution abnormalities in the cerebellum or
brain [15], and various assays suggest that SETX absence produces only
modest if any effects on transcription termination [16].
A growing body of evidence suggests that SETX forms nuclear foci
during the S/G2 transition phase of the cell-cycle, indicative of replica-
tion stress at collision sites between the DNA replisome and transcription
machinery [17, 18]. Indeed, such nuclear foci are reduced by transcrip-
tion inhibition and increased by impaired DNA replication [18]. There is
also evidence that SETX has retained a link to the nuclear RNA exosome,
as we and others have documented that SETX binds to Exosc9 [19,20],
and shown that SETX co-depletion occurs when Exosc9 or Exosc10 are
depleted [20]. SETX also appears to be regulated by the sumoylation
pathway [19], as SUMO modification is required for SETX interaction
with the RNA exosome [20]. SETX may perform a related function in G0
neurons to those delineated within cycling cells. For example, RNA Po-
lymerase II (RNAP II) undergoes self-collision in regions where positive
strand and negative strand transcription overlaps [21], including where
non-coding regulatory RNAs are transcribed in the antisense direction. A
role for SETX at sites of RNAP II collisions may prove particularly
important for active neurons as part of the aging process, given the large
number of long brain-specific transcripts [22].
SETX is a very low-abundant protein with <500 molecules/cell,
similar to its homologue, IGHMBP2 [23]. Protein levels of SETX and its
yeast homologue, Sen1p, are tightly regulated, such that large increases
in mRNA levels fail to significantly increase protein levels [24, 25].
Despite this, transient transfection in cell culture can boost SETX protein
levels on an individual cell basis. Here we examined the subcellular
localization of GFP- and Flag-tagged SETX in HEK293 cells, and found
that SETX showed localization to the nucleoplasm. However, when we
co-stained for the nucleolus markers fibrillarin or B23, they both dis-
played diffuse redistribution from the nucleolus to the nucleoplasm upon
SETX over-expression. This redistribution occurred at a frequency as high
as 90% at 24- and 72-hours post-transfection, regardless of whether the
epitope tag was GFP or Flag. Importantly, enzymatically dead SETX had
no effect on nucleolus marker localization. While we observed dissolu-
tion of the nucleolus in cells over-expressing SETX, recombinant SETX
itself remained in the nucleoplasm. By monitoring cell-cycle progression
using propidium iodide and flow cytometry, we were able to attribute
this phenomenon to a block in cell-cycle progression.
2. Material & methods
2.1. SETX expression constructs
We created a GFP-tagged SETX construct for subcellular localization
studies. Full cloning details of our original Flag-tagged SETX construct
were outlined previously [26]. To generate a GFP tagged SETX construct
we PCR amplified eGFP from an eGFP Clontech vector. The upstream
primers contained a 50-prime extension that encoded FLAG tag. The
downstream primer contained the Not I site. In a second amplification
step, an extension primer is used to add the additional Flag tags and
includes a Nhe I for ease of cloning. Finally we took the re-derived
3xFlag-GFP containing eGFP vector and digested out the entire CMV
3xFlag-eGFP-Flag-SETX segment by Kpn I/Mlu I digestion and ligated this
into the same restriction enzyme sites of our previously reported
Flag-SETX construct [26]. For the mini-SETX construct, the eGFP coding
sequence was inserted into our existing Flag-SETX construct at Bgl II
restriction enzyme sites. This represents an internal deletion of 1114
residues from the SETX protein (residues 717 to 1831), which was
replaced with 231 residues of eGFP. This means that the mini-SETX
construct still retains the N-terminus domain (residues 1–500) [5]; (ii)
the helicase domain (residues 1931–2456) [5] and the Nuclear Locali-
zation Signal (residues 2661–2677) [26]. The P-LoopΔ-SETX construct
was generated using the Gibson Assembly Cloning Kit (NE BioLabs™) to2affect an eight amino acid deletion (GPPGTGKS) of the SETX GTP/ATP
binding domain. We PCR amplified Chloramphenicol selection cassette
and incorporated SETX targeting sequence either side of the deletion
region along with Asc I 8-bp restriction sites not present in our Flag-SETX
construct. The final step involved Asc I digestion, following by DNA
ligation to delete out the P-Loop and replace it with one Asc I site and a
single T base to maintain the correct coding frame. All constructs
generated by our group were validated by DNA Sanger sequencing.2.2. Cell culture and transfections
HEK293A and HeLa cells were grown in DMEMmedia with 10% FBS.
In all transfections with SETX constructs, endogenous SETX was still
present in the cell culture. Transfections were performed using Lip-
ofectamine 2000, according to the manufacturer's instructions (Invi-
trogen). The media was replaced after 4 h. Hek293A cells were not
synchronized prior to cell cycle analysis.
Transfections efficiency with SETX based expression constructs were
relatively low. The SETX open reading frame (orf) is large at 8034-bp.
Thus, transfection efficiency based upon all SETX expression constructs
(GFP-SETX, Flag-SETX, GFP-mini-SETX and Flag-P-loopΔ-SETX) were
~30% based upon fluorescent microscopy and random field counting.2.3. Immunocytochemistry
Cells were seeded into 24-well plates containing glass circle cover
slips (Thermo Fisher) prior to experimentation. Cells were transfected
when ~50% confluent as indicated. PBS-MC buffer was used for all
washes and as a diluent for all solutions. Cells were fixed with 4%
paraformaldehyde in PBS-MC for 21-min. Cells were permeabilized for 5-
min in 0.2% Triton-X in PBS, then placed in blocking solution (5%
Normal Goat Serum and 5% BSA in PBS) for 1-hr. Primary and secondary
antibodies were diluted in 5% normal goat serum in PBS-MC. Cells were
incubated with primary Ab's O/N at 4 C. Cells were washed with PBS-
MC and then incubated in secondary Ab's for 1-hr. Next, cells were
counter stained with a 1:20,000 solution of DAPI in PBS for 10-min.
Finally, cover slips were washed once with PBS-MC and mounted on
slides. Images were captured with a Zeiss LSM 780 confocal microscopy
and analyzed with Zen 2011 LSM 780 software. Ab's used include: (i)
fibrillarin mAb (Gene Tex: GTX24566); B23 mAb (ProteinTech: 60096-
1); Flag mAb (Sigma: F3165); fibrillarin rabbit-Alexa 488 conjugate
(Cell Signaling: C13C3).2.4. PI staining for FACS analysis
A 6-cm petri dish of confluent Hek293A cells were harvested 24-hr
after GFP transfection and washed with 2 ml of ice-cold PBS. Cell were
fixed in -20 C 70% ethanol for 30-min, with mild vortexing every 10-min
to prevent cells from clumping. Fixed cells were centrifuged at 2000-rpm
for 5-min and washed a further two times with 1-ml of PBS. Cells were
then re-suspended in 800μl PI staining solution at 4 C for 20-min in the
dark. Samples with filtered with a 35μm nylon mesh snap/cap tube prior
to loading onto the BD LSR Fortessa instrument.2.5. Statistical analysis
All data were prepared for analysis with Microsoft Excel. Statistical
analysis was done using Microsoft Excel or Prism 4.0. For ANOVA, if
statistical significance (P < 0.05) was achieved, we performed post-hoc
analysis to account for multiple comparisons. For the analysis of Fibril-
larin and B23 being localized distinctly to the nucleolus or the nucleo-
plasm (Figure 2B), we performed three distinct transfections. Thereafter,
we pooled the results for a total count of n  50 for GFP-SETX positive,
GFP-mini-SETX positive, or non-transfected cells respectively.
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3.1. SETX over-expression in HEK293A cells linked with nucleolus
dissolution
To track SETX subcellular localization, we developed a GFP-tagged,
full-length expression construct. We tested if SETX might show nucle-
olus localization, based upon initial yeast Sen1p experimentation [26,
27]. There is growing interest in the nucleolus, as disruption of this
structure has been implicated in ALS linked to mutations in various
RNA-binding proteins and C9orf72 dipeptide repeats [28, 29]. We
transiently transfected HEK293A cells with GFP-SETX and found nucle-
oplasm localization (Figure 1A). Unexpectedly, in the vast majority of
transfected cells, fibrillarin redistributed from the nucleolus to the
nucleoplasm just 24 h after transfection (Figure 1A). We then examined
the marker B23 as a sensitive marker of nucleolus toxicity [30]. We found
that with GFP-SETX transfection, B23 was similarly redistributed from
the nucleolus to the nucleoplasm (Figure 1B). We found no evidence of
apoptosis mediated cell death such as chromosome condensation, nor
any evidence of cellular morphological changes linked with GFP-SETX
transfection.
To rule out GFP artifacts, we developed a GFP ‘mini-SETX’ control
containing a large 1114 amino acid internal deletion, replaced with the
GFP coding region. GFP-mini-SETX transfection showed partial mis-
localization to the cytosol (Figure 2A), and failed to disrupt nucleolar
appearance (Figure 2A). To measure the frequency of nucleolar to
nucleoplasm marker redistribution, we performed three independent
transfections with the following constructs: (i) GFP-SETX; (ii) GFP-mini-
SETX; and (iii) non-transfected control. We counted at least 50 GFP-
positive cells counterstained for fibrillarin or B23, as well as 50 non-
transfected control cells. Non-transfected cells showed a normal nucle-
olar staining pattern for B23 and fibrillarin at 97% and 99% respectively.
For GFP-SETX, the B23 and fibrillarin nucleolus staining appeared
normal in only 10% of transfected cells. However, for GFP-mini-SETX
transfected cells, nucleolus staining appeared normal for B23 in 88% of
cells and for fibrillarin in 93% of cells (Figure 2B). Although the3percentage of cells with B23 and fibrillarin distinctive nucleolus staining
was dramatically reduced in GFP-SETX transfected cells compared with
controls (P < 0.01), GFP-mini-SETX transfected cells were comparable to
non-transfected controls (Figure 2B).
3.2. SETX disruption of the nucleolus requires an intact helicase domain
For further controls, we transfected both GFP-SETX and Flag-SETX
into HEK293A cells, and observed that over-expression of SETX results
in disruption of the nucleolus, regardless of the epitope tag (Figure 3A).
To determine if SETX disassembly of the nucleolus was simply due to
random proteotoxicity, we derived a helicase-dead version of SETX by
deleting eight residues (p.1963–1970) that comprise the P-Loop GTP/
ATP binding motif [5], and found that transfection of HEK293A cells
with P-LoopΔ-SETX did not affect fibrillarin nucleolar localization
(Figure 3B). Quantification of fibrillarin and B23 in transfected cells as
represented in Figures 3A – 3B, were treated similarly as depicted in
Figure 2B (see methods). Taken together, these results indicate that: (i)
SETX induced disruption of the nucleolus is not dependent on the GFP
tag; (ii) nucleolus disruption is dependent upon an active SETX helicase
domain; and (iii) P-LoopΔ-SETX, like GFP-mini-SETX, shows occasional
mislocalization to the cytosol (white arrows, Figure 3B). This is a phe-
nomena unrelated to lack of SETX as treatment of cell culture with siRNA
to deplete SETX protein levels [25], has no impact on B23 staining or
nucleolus linked, cell-cycle progression (data not shown).
3.3. SETX disassembly of the nucleolus is linked with cell-cycle arrest
We considered two possible explanations for SETX induced nucleolus
disassembly, as follows: (i) elevated SETX levels are toxic to the nucleolus
in a manner similar to that of C9orf72 repeat expansion associated GR or
PR dipeptides [28, 29]; or (ii) elevated SETX levels may induce an
S-phase cell-cycle block [31]. DAPI nuclear staining did not reveal any
evidence for increased apoptosis in GFP-SETX transfected cells even after
72 h of transfection. In addition, we noted that the typical prophase
related nucleolus marker redistribution in a small percentage ofFigure 1. SETX over-expression in HEK293A cells
results in the redistribution of nucleolus markers
fibrillarin and B23. (A) HEK293A cells were trans-
fected with GFP-SETX (green) and 24 h later cells
were immunostained with anti-fibrillarin Ab (red)
which marks the nucleolus and DAPI (blue) to define
the nucleus. Yellow arrows indicate fibrillarin signal
dispersed throughout the nucleoplasm in cells
expressing recombinant SETX. Scale bar ¼ 10μM. (B)
The nucleolus marker B23 (red) was also seen as
diffuse signal throughout the nucleoplasm, co-
incident with GFP-SETX expression. Scale bar ¼
10μM.
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Figure 2. GFP-mini-SETX expression in HEK293A
cells does not perturb the nucleolus, and GFP-SETX,
but not by GFP-mini-SETX, is linked with nucleolus
disassembly. (A) HEK293A cells were transfected with
GFP-mini-SETX, and immunostained with anti-
fibrillarin Ab (Red). Note that cells clearly positive
for GFP (mini-SETX) show a normal fibrillarin nucle-
olus staining pattern. Rare exceptions include one cell
in G2/mitosis (white asterisk) and a second cell that is
weakly GFP positive but is likely entering S-phase
(yellow asterisk). Scale bar ¼ 10μM. (B) To gauge
frequency, we repeated the GFP-SETX(SETX) and GFP-
mini-SETX(mini-SETX) transfections three times and
counted at least 50 GFP-positive cells. For untrans-
fected cells, B23 and fibrillarin showed normal
nucleolar staining 97% and 99% of the time, respec-
tively. For GFP-mini-SETX transfected cells, B23 and
fibrillarin showed normal nucleolar staining 88% and
93% of the time, respectively. However, for GFP-SETX
transfected cells, B23 and fibrillarin showed a normal
nucleolus staining pattern only 10% of the time for
both markers. **P < 0.01; ANOVA with post-hoc
Tukey test, while GFP-mini-SETX was not signifi-
cantly different versus control.
Figure 3. Flag-SETX expression in HEK293A cells
linked with nucleolus dissolution, while helicase-dead
SETX is not. (A) HEK293A cells were transfected with
Flag-SETX and immunostained with anti-Flag anti-
body (red) 24 h after transfection. Fibrillarin signal
was detected with the rabbit Alexa-488 conjugate
antibody (green). Cells transfected with Flag-SETX
show disassembly of the nucleolus (yellow arrows).
Scale bar ¼ 10μM. (B) HEK293A cells were trans-
fected with P-LoopΔ-SETX (deletion p.1963-p.1970)
which lacks the ATP/GTP binding domain, and 24 h
later cells were prepared for anti-fibrillarin-488
(green) and anti-Flag (red) antibody visualization.
Scale bar ¼ 10μM.
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Figure 4. SETX over-expression in HEK293A cells causes S-phase cell-cycle
arrest. We analyzed 133,759 total events sorted from GFP-SETX transfected
HEK293A cells and removed cell debris and doubles with forward-scatter and
side-scatter gating to isolate single viable cells (107,136). The FITC-A signal cut-
off to define GFP-negative cells (GFP-) was defined from non-transfected
HEK293A controls. (A) The PI signal (695/40 BP) was plotted for 70,869
GFP- cells from the GFP-SETX transfection. This histogram shows a typical
distribution of cycling-cells, with the highest cell count representing G1 cells
(47%), a smaller peak for cells in G2/Mitosis (19%) and a partially overlapping
S-phase cells (34%). (B) 10,000 GFP-positive cells (GFPþ) were gated and PI
signal was plotted. The GFP-SETX þ cells show a very large shift from G1 (29%)
into S-phase (62%), which largely do not enter G2/M-phase (9%). We performed
Chi-squared analysis, and found that the results were highly significant (χ2 >
2961.5; P < 0.0001).
C.L. Bennett et al. Heliyon 6 (2020) e04165non-transfected cells (Figure 2A, yellow asterisk), was very similar to
what we saw in the majority of SETX transfected cells. To test if SETX
over-expression interferes with cell cycle progression, we repeated the
transfection experiment and performed propidium iodide (PI) staining
and flow cytometry. GFP-negative signal was defined from
non-transfected cells. 133,759 total events were sorted from GFP-SETX
transfected Hek293A cells to remove cell debris and cell doublets with
forward-scatter (P1, 18%) and side-scatter (P2, 2%) gating to isolate
viable single cells (P3) ¼ 107,136. The PI signal (675/25BP) was plotted
for 70,869 GFP-negative cells. 10,000 GFP-positive cells (GFPþ) were
gated and PI signal was plotted. When we compared GFP-SETX trans-
fected versus for non-transfected (GFP negative) cells within the same
culture, we noted a marked reduction in the percentage of G1 cells
(~29% vs. ~47% for non-transfected cells) and a dramatic increase in
the percentage of cells in S-phase (~62% vs. 34% for non-transfected
cells), based upon plotting of the PI signal (Figure 4). The percentage
of cells in G2/M-phase was only 9% for GFP-SETX positive cells versus
19% for GFP-negative cells. This represents a highly significant differ-
ence in cell cycle progression (P < .0001 by χ2 analysis). Hence, redis-
tribution of fibrillarin and B23 from the nucleolus to the nucleoplasm
upon SETX over-expression is likely due to a block in cell-cycle pro-
gression at S-phase [18].
4. Discussion
SETX is critical to neuron survival, as both recessive and dominant
mutations result in neurodegenerative disease. In addition, SETX biology
is also important to age-related maintenance of genome stability.
Despite its large size, GFP-tagged SETX can be effectively transfected
into Hek293 cells, where it localized to the nucleoplasm as previously
shown [18]. However, transfection of Flag- and GFP-tagged SETX had a
dramatic effect on the localization of two prominent markers of the
nucleolus, fibrillarin and B23, which were redistributed to the nucleo-
plasm in the vast majority of transfected cells. In GFP-SETX transfected
cells, the appearance was typical of prophase nucleolus disassembly [31].
We found no evidence to support nucleolus toxicity or a general induc-
tion of apoptosis mediated cell death. But it is interesting to note that
previous studies with Sen1p, the yeast orthologue to SETX: that inacti-
vation of Sen1p by temperature shift of a strain carrying sen1-1 leads to
mislocalization of two nucleolar proteins, Nop1 (yeast fibrillarin) and
Ssb1 [32]. To investigate our hypothesis that SETX over-expression
induced cell-cycle arrest, we employed flow cytometry and found that
indeed GFP-SETX positive cells showed a clear shift from the normal
bimodal distribution in cycling cells (G1, S-phase, G2/M), to a pattern
characteristic of S-phase arrest [33]. In addition, we found that a func-
tional SETX helicase domain was required to induce S-phase arrest, as
deletion of the P-Loop GTP/ATP binding motif completely abolished the
effect.
The SETX helicase is known to form S/G2 phase foci where it is
thought to direct incomplete RNA transcripts to the nuclear exosome for
degradation [20], particularly at sites of DNA pol – RNAP II collision
[18]. In addition, the DNA damage response proteins with which SETX
may interact are poorly understood. Thus, upon even modest protein
level elevation, SETX may sequester essential proteins that trigger
S-phase arrest. Our confocal microscopy and FACS analysis demonstrate
that once functional SETX protein is raised beyond a minimum threshold,
S-phase arrest is induced. But due to the overt effect that transfected
SETX has on an individual cell basis, combined with the reduced trans-
fection efficiency, it remains technically difficult to define the specific
level of SETX elevation required to induce S-phase arrest. This phe-
nomenon may reflect SETX's role at S/G2 phase foci, which strongly
co-localize with 53BP1 and γH2AX, two protein markers of spontaneous
DNA lesions and transcriptionally active nuclear bodies [18].
We and others have previously demonstrated SETX-exosome in-
teractions [19, 20], and directing nascent RNAs to the nuclear exosome at
S-phase foci may be critically important. This process may be highly5sensitive to SETX protein levels, potentially explaining its tight regula-
tion. Although such processes are obviously crucial for cycling cells, how
would SETX-exosome interactions affect neurons? As it turns out, RNAP
II undergoes self-collision in regions where positive and negative strand
transcription overlaps [21]. Regulation of convergent transcription in
neurons might be sensitive to defects in SETX function, or expression
levels. In neurons, where long transcripts are known to be enriched [34],
RNAP II self-collisions would occur more frequently, underscoring a
potentially key role for SETX function that may be linked with disease.
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